Lovastatin-induced acute rhabdomyolysis

Area of Science:

• Pharmacology
• Toxicology
• Cardiovascular Medicine

Background:

• Statins, like lovastatin, are widely prescribed for hyperlipidemia.
• Rhabdomyolysis is a rare but serious side effect of statin therapy.
• Drug interactions can potentiate statin-induced toxicity.

Observation:

• A case of severe rhabdomyolysis occurred in a 79-year-old patient.
• The patient experienced respiratory and renal failure.
• These complications arose three weeks after starting low-dose lovastatin.

Findings:

• Low-dose lovastatin therapy was initiated in a 79-year-old, non-immunocompromised patient.
• Severe rhabdomyolysis complicated by respiratory and renal failure developed.
• Concomitant gemfibrozil use was noted and may be a contributing factor.

Implications:

• This case highlights the potential for severe adverse events even with low-dose statins.
• The combination of lovastatin and gemfibrozil warrants careful consideration due to increased risk.
• Physicians should be vigilant for signs of rhabdomyolysis in patients on statin therapy, especially with concurrent gemfibrozil use.